B-Cell NHL
Advertisement
Tisa-Cel Found Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
Read More
Evaluating Mosunetuzumab and Polatuzumab Vedotin in Relapsed/Refractory B-Cell NHL
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Mosunetuzumab was safe and efficacious for patients with heavily pretreated relapsed and/or refractory B-cell ...
Read More
CAR T-Cell Therapy Tisa-Cel Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 9, 2022
Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...
Read More
Advertisement
Advertisement
Latest News

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

May 14, 2025

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

May 13, 2025

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

May 12, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |